Novo Nordisk Ziltivekimab Fails ZEUS Phase 3: IL-6 Cardio Hypothesis Collapses

What Happened

Novo Nordisk (NYSE: NVO) announced this morning that ziltivekimab missed the primary endpoint of the Phase 3 ZEUS cardiovascular outcomes trial. The once-monthly subcutaneous IL-6 ligand inhibitor failed to reduce major adverse cardiovascular events (MACE) versus placebo in over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP at or above 2 mg/L).

The hazard ratio for MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke, was 0.99 with a 95% confidence interval of 0.88 to 1.11. That is a dead flat result. No signal. No trend. The drug hit its molecular target but the target did not matter for the endpoint that counts.

NVO closed at $51.61 on July 30. The press release hit at 7:20 AM EDT on July 31. NVO subsequently closed at $47.08 on July 31 (Polygon), down 8.8% on the day following the ZEUS failure announcement. (Novo Nordisk press release via GlobeNewswire)

The Numbers

Metric	Result
Trial	ZEUS Phase 3 (NCT05021835)
Drug	Ziltivekimab 15 mg SC once monthly
Comparator	Placebo
Enrollment	6,300+ patients
Primary endpoint	MACE (CV death, non-fatal MI, non-fatal stroke)
Hazard ratio	0.99 (95% CI: 0.88 to 1.11)
Biomarker response	Free IL-6 and hsCRP reduced as expected
Safety signal	Higher serious infections vs placebo

Ziltivekimab did what it was designed to do at the molecular level. Free IL-6 dropped. hsCRP dropped. The anti-inflammatory mechanism was confirmed. But reducing inflammation in this patient population did not translate into fewer heart attacks, strokes, or cardiovascular deaths. The disconnect between biomarker engagement and clinical outcomes is the same pattern that has killed cardiovascular anti-inflammatory programs for years. (ClinicalTrials.gov NCT05021835)

Why It Matters

This is the second high-profile pipeline failure for Novo Nordisk this summer. Oral semaglutide failed both Phase 3 EVOKE trials in Alzheimer’s disease in late 2025, a result detailed in our earlier analysis. Now ziltivekimab, the IL-6 inhibitor Novo acquired through its $2.1 billion Corvidia Therapeutics buyout in 2020, has failed its first cardiovascular outcomes readout.

Analysts had been optimistic. Guggenheim Securities assessed success as “highly likely” in a July 13 note, defining a clinically significant benefit as a hazard ratio of 0.85. BMO Capital Markets put the odds of at least a 15% benefit at 55% earlier this week. The actual hazard ratio was 0.99. Consensus peak sales estimates for ziltivekimab sat around $3 billion, with both Guggenheim and BMO calling the CKD opportunity “multibillion-dollar.”

The failure weakens Novo’s push to diversify beyond GLP-1 obesity and diabetes drugs. BMO analysts noted before the readout that ziltivekimab was “an important opportunity for Novo to extend its cardiovascular presence beyond obesity/diabetes, and establish a differentiated position in inflammation-driven cardiovascular disease.” That opportunity is now in serious doubt. (FierceBiotech coverage)

Novo stated the ZEUS outcome will not affect its previously communicated adjusted operating profit outlook for 2026, though it will trigger a Q3 noncash impairment charge.

What to Watch Next

Two ongoing Phase 3 trials are keeping the ziltivekimab program on life support. The HERMES trial is testing the drug in heart failure, and the ARTEMIS trial is evaluating it in patients following an acute heart attack. Both are scheduled to deliver data in the first half of 2027. BMO analysts wrote Friday that they now “view it as unlikely that either will read out positively.”

If HERMES and ARTEMIS also fail, Novo’s IL-6 cardiovascular program is finished. The company may then step up M&A activity to fill the pipeline gap, with BMO suggesting a large deal in cardiovascular, metabolic, or rare disease could help shift investor attention away from the GLP-1 hyper-focus. The Mim8 hemophilia A PDUFA remains pending as of July 31.

Full ZEUS results will be presented at an upcoming scientific meeting in 2026.